Immohr Moritz Benjamin, Boeken Udo, Mueller Franziska, Prashovikj Emir, Morshuis Michiel, Böttger Charlotte, Aubin Hug, Gummert Jan, Akhyari Payam, Lichtenberg Artur, Schramm René
Department of Cardiac Surgery, Medical Faculty, Heinrich Heine University, Moorenstrasse 5, Duesseldorf, 40225, Germany.
Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center North Rhine-Westphalia, Georgstrasse 11, Bad Oeynhausen, 32545, Germany.
ESC Heart Fail. 2021 Apr;8(2):1253-1262. doi: 10.1002/ehf2.13188. Epub 2021 Jan 21.
Heart transplantation (HTx) represents optimal care for advanced heart failure. Left ventricular assist devices (LVADs) are often needed as a bridge-to-transplant (BTT) therapy to support patients during the wait for a donor organ. Prolonged support increases the risk for LVAD complications that may affect the outcome after HTx.
A total of 342 patients undergoing HTx after LVAD as BTT in a 10-year period in two German high-volume HTx centres were retrospectively analysed. While 73 patients were transplanted without LVAD complications and with regular waiting list status (T, n = 73), the remaining 269 patients were transplanted with high urgency status (HU) and further divided with regard to the observed leading LVAD complications (infection: HU1, n = 91; thrombosis: HU2, n = 32; stroke: HU3, n = 38; right heart failure: HU4, n = 41; arrhythmia: HU5, n = 23; bleeding: HU6, n = 18; device malfunction: HU7, n = 26). Postoperative hospitalization was prolonged in patients with LVAD complications. Analyses of perioperative morbidity revealed no differences regarding primary graft dysfunction, renal failure, and neurological events except postoperative infections. Short-term survival, as well as Kaplan-Meier survival analysis, indicated comparable results between the different study groups without disadvantages for patients with LVAD complications.
Left ventricular assist device therapy can impair the outcome after HTx. However, the occurrence of LVAD complications may not impact on outcome after HTx. Thus, we cannot support the prioritization or discrimination of HTx candidates according to distinct mechanical circulatory support-associated complications. Future allocation strategies have to respect that device-related complications may define urgency but do not impact on the outcome after HTx.
心脏移植(HTx)是晚期心力衰竭的最佳治疗方法。左心室辅助装置(LVADs)常作为桥接移植(BTT)疗法,在等待供体器官期间支持患者。长期支持会增加LVAD并发症的风险,这可能会影响HTx后的结果。
回顾性分析了德国两个大容量HTx中心在10年期间共342例接受LVAD作为BTT后进行HTx的患者。73例患者在无LVAD并发症且处于常规等待名单状态下接受移植(T组,n = 73),其余269例患者在紧急状态下接受移植(HU组),并根据观察到的主要LVAD并发症进一步分组(感染:HU1组,n = 91;血栓形成:HU2组,n = 32;中风:HU3组,n = 38;右心衰竭:HU4组,n = 41;心律失常:HU5组,n = 23;出血:HU6组,n = 18;装置故障:HU7组,n = 26)。LVAD并发症患者的术后住院时间延长。围手术期发病率分析显示,除术后感染外,原发性移植物功能障碍、肾衰竭和神经系统事件方面无差异。短期生存率以及Kaplan-Meier生存分析表明,不同研究组之间结果相当,LVAD并发症患者无劣势。
左心室辅助装置治疗可能会损害HTx后的结果。然而,LVAD并发症的发生可能不会影响HTx后的结果。因此,我们不支持根据与机械循环支持相关的不同并发症对HTx候选者进行优先排序或区别对待。未来的分配策略必须认识到,与装置相关的并发症可能决定紧迫性,但不会影响HTx后的结果。